Stem-cell start-ups seek to crack the mass-production problem

Photo: iPS cells in the lab. Photo credit: CSIRO via Wikimedia – CC BY 3.0. Article by Eric Bender. Nature – September 29, 2021.

Commercial outfits are building the tools and know-how to manufacture treatments using induced pluripotent stem cells in the quantities required for clinical use.

In the laboratory, induced pluripotent stem (iPS) cells can seem like magic: derived from differentiated cells, they can then morph into surprisingly good replacements for pancreatic, brain, eye, heart and other cells. Some are being used in clinical trials to treat people with chronic conditions, including diabetes and Parkinson’s […]

Click here to view original web page at www.nature.com